利培酮治疗不同性别精神分裂症患者的疗效及不良反应观察

目的：探讨利培酮治疗不同性别精神分裂症的疗效和安全性。方法：收集103例精神分裂症患者，男61例、女42例，给予利培酮治疗观察8周，分别于治疗前和治疗第2、4、6、8周末采用PANSS量表进行评分，分别于治疗前、治疗后8周末检测患者的血生化指标和体重，同时观察记录患者的不良反应。结果：男性精神分裂症患者的临床治愈率明显高于女性患者（P ＜0.05）。随着治疗时间的延长，男女性患者治疗后的PANSS评分均明显低于治疗前（P ＜0.01）；男性患者治疗前的PANSS评分明显高于女性患者（P ＜0.01）；治疗8周末，男性患者的PANSS评分明显低于女性患者（P ＜0.05）。男性精神分裂症患者治疗后的阳性量表评分、一般精神病量表评分明显低于女性精神分裂症患者治疗后（P ＜0.05，P ＜0.01）。男（60.6%，37/61）、女（57.1%，24/42）性患者使用利培酮的不良反应均以锥体外系症状为主，但男性、女性锥体外系不良反应比较差异无统计学意义（P ＞0.05）。男、女性患者治疗前后空腹血糖、餐后2h血糖、甘油三酯、体重比较差异均无统计学意义（P ＞0.05）。结论：利培酮对男、女性精神分类症患者均由治疗效果，且对男性患者的疗效优于女性患者，治疗的不良反应以锥体外系症状为主。

THERAPEUTIC AND ADVERSE EFFECTS OF RISPERIDONE IN TREATMENT OF DIFFERENT GENDER PATIENTS WITH SCHIZOPHRENIA

Objective： To investigate the therapeutic effects and security of risperidone in treatment of different gender patients with schizophrenia.Methods：103 schizophrenia patients （men 61 cases, women 41 cases） were treated with risperidone for 8 weeks. The PANSS scale was used to evaluate the therapeutic effects before treatment, and respectively 2-week, 4-week, 6-week and 8-week after treatment. The body weight and blood biochemical indexes were measured before and after treatment, and also observed adverse effects.Results：For male patients, the clinical cure rate was obviously higher than female patients （P〈0.05）. With extension of treatment time, the PANSS score of male and female patients were all obviously lower than that before treatment （P〈0.01）; before treatment the PANSS score of male patients was significantly higher than that of female patients（P〈0.01）, while after treatment the PANSS score of male patients was significantly lower than that of female patients（P〈0.05）. After treatment, the SAPS score and general psychiatric scale score were all significantly lower than that of female patients（P〈0.01, P〈0.05）. The main adverse effects of risperidone was extrapyramidal symptoms, and there had no statistical significance between the extrapyramidal symptoms of male （60.6%, 37/61） and female （57.1%, 24/42） patients （P〉0.05）. Before and after treatment, the fasting blood glucose, 2h postprandialbloodglucose,triglycerideandbodyweightofmaleandfemalepatientshadnostatisticalsignificance（P〉0.05）. Conclusions： Risperidone has therapeutic effects for male and female patients with schizophrenia, and the therapeutic effects for malepatientsisbetterthanfemalepatients.Themain adverse effects ofrisperidone are extrapyramidal symptoms.